Fluicell AB (SE:FLUI)
:FLUI
Want to see SE:FLUI full AI Analyst Report?
FLUI Stock Chart & Stats
kr10.00
>-kr0.01(-1.38%)
At close: 4:00 PM EST
kr10.00
>-kr0.01(-1.38%)
Day’s Range― - ―
52-Week Rangekr7.45 - kr30.00
Previous CloseN/A
Volume175.18K
Average Volume (3M)16.23K
Market Cap
kr18.41M
Enterprise Valuekr16.15M
Total Cash (Recent Filing)kr2.26M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.14
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding1,373,703
10 Day Avg. Volume8,193
30 Day Avg. Volume16,225
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)74.56
Price to Sales (P/S)135.42
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr68.60M
Bulls Say, Bears Say
Bulls Say
Low LeverageA zero-debt capital structure meaningfully reduces refinancing and interest risk, preserving strategic optionality. Over 2–6 months this supports runway management and gives management flexibility to raise equity or execute partnerships without near-term covenant pressure.
Revenue ReboundA strong TTM revenue recovery signals improving commercial traction and market acceptance of core microfluidic tools. Sustained top-line growth over months can enable scale benefits, justify further R&D investment, and narrow the gap to eventual profitability if margins improve.
Specialized Product PlatformFluicell's microfluidics platform targets high-value single-cell and regenerative medicine niches with technical barriers to entry. This structural specialization supports differentiated product-market fit, recurring instrument and consumable opportunities, and durable demand from academia and industry customers.
Bears Say
Cash BurnPersistent negative operating and free cash flow indicate ongoing cash burn and likely reliance on external financing. Over the medium term this increases dilution risk, limits self-funded growth initiatives, and constrains the company's ability to invest in commercialization or weather setbacks.
Sustained LossesMaterial and continued operating losses show the business remains unprofitable and must progress to breakeven to be self-sustaining. Over 2–6 months persistent losses will pressure cash reserves, strategic choices and could delay or force concessions in commercial expansion.
Eroding Equity BaseDeclining shareholders' equity and negative ROE signal capital erosion from losses, reducing the balance sheet buffer. This weaker equity base limits resilience to shocks, narrows financing alternatives, and increases the urgency of external funding or rapid margin improvement.
FLUI FAQ
What was Fluicell AB’s price range in the past 12 months?
Fluicell AB lowest stock price was kr7.45 and its highest was kr30.00 in the past 12 months.
What is Fluicell AB’s market cap?
Fluicell AB’s market cap is kr18.41M.
When is Fluicell AB’s upcoming earnings report date?
Fluicell AB’s upcoming earnings report date is May 08, 2026 which is in 7 days.
How were Fluicell AB’s earnings last quarter?
Fluicell AB released its earnings results on Feb 20, 2026. The company reported kr0.074 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.074.
Is Fluicell AB overvalued?
According to Wall Street analysts Fluicell AB’s price is currently Overvalued.
Does Fluicell AB pay dividends?
Fluicell AB does not currently pay dividends.
What is Fluicell AB’s EPS estimate?
Fluicell AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fluicell AB have?
Fluicell AB has 1,373,703 shares outstanding.
What happened to Fluicell AB’s price movement after its last earnings report?
Fluicell AB reported an EPS of kr0.074 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.789%.
Which hedge fund is a major shareholder of Fluicell AB?
Currently, no hedge funds are holding shares in SE:FLUI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fluicell AB
Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.